Treatment of Aggressive Non-Hodgkin’s Lymphoma: A North American Perspective
Treatment of Aggressive Non-Hodgkin’s Lymphoma: A North American Perspective
The most common subtype of aggressive non-Hodgkin’s lymphoma is diffuse large B-cell lymphoma (DLBCL). Diffuse large B-cell lymphoma represents a heterogeneous entity, with 5-year overall survival rates ranging from 26% to 73%. Microarray gene expression studies have confirmed that biologically distinct subgroups exist within DLBCL, and can be correlated with outcome. Initial management is usually guided by stage of disease at presentation. Approximately 25% of patients with DLBCL present with limited-stage disease and are treated with combined-modality therapy (brief chemotherapy and involved-field radiation). Most patients present with advanced-stage disease and require treatment with an extended course of chemotherapy. The CHOP (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone) chemotherapy regimen has been the mainstay of therapy since its development in the 1970s, as more intensive chemotherapy regimens failed to show additional benefit. The era of monoclonal antibodies has transformed treatment practices for aggressive lymphoma and has led to a significant improvement in outcome. A randomized trial comparing the use of rituximab (Rituxan), a chimeric anti-CD20 IgG1 monoclonal antibody, combined with CHOP chemotherapy vs CHOP chemotherapy alone for elderly patients with advanced-stage DLBCL demonstrated a significant benefit for the combination approach. This finding has now been confirmed in two additional randomized, controlled trials and a population-based analysis, making CHOP and rituximab the standard of care for all newly diagnosed patients with DLBCL. Despite this advance, newer therapies are needed and many are under active investigation. The insights gained from molecular techniques such as gene expression profiling should permit identification of additional lymphoma-specific therapeutic targets and the development of novel agents that take into account underlying biology and allow for greater tailoring of therapy.
The World Health Organization (WHO) classification of non- Hodgkin's lymphoma (NHL) recognizes more than 30 different subtypes of NHL. The term aggressive NHL refers to those subtypes that grow rapidly (proliferation index > 40%) and would often be fatal within months without appropriate therapy. The most common subtype of aggressive NHL is diffuse large B-cell lymphoma (DLBCL), which will be the main focus of this review. Diffuse large B-cell lymphoma accounts for approximately 30% to 40% of all newly diagnosed cases of NHL and more than 80% of aggressive lymphomas.[ 1] Prognosis Diffuse large B-cell lymphoma represents a heterogeneous entity. Multiple morphologic variants are recognized within the WHO classification, and patients exhibit a wide range of clinical presentations. The International Prognostic Index (IPI) remains the primary clinical tool used for predicting outcome for aggressive NHL. Based on the number of negative prognostic features present at the time of diagnosis (age > 60 years, stage III/IV disease, elevated lactatedehydrogenase [LDH] level, Eastern Cooperative Oncology Group [ECOG] performance status ≥ 2, more than one extranodal site of disease), the 5-year overall survival rate rangesfrom 26% to 73%. Only about half of all presenting patients will be cured of their lymphoma. The clinical factors conferring poor prognosis are likely surrogate vari-ables for intrinsic molecular heterogeneity. Multiple molecular markers, such as overexpression of bcl-2 and bcl-6, have been shown to be predictive of outcome in DLBCL. More recently, microarray gene expression studies have confirmed that biologically distinct subgroups exist within DLBCL, and can be correlated with outcome.[4-7] Alizadeh and colleagues demonstrated that at least two major subtypes can be recognized based on the pattern of gene expression: one with a gene expression profile similar to normal germinal center B cells (GCB), and the other mimicking activated peripheral blood B cells (ABC).[4,5] Patients with the GCB profile have a significantly better overall survival, and the gene expression pattern provided additional prognostic information independent of the IPI. Several investigators have used the information provided through gene array studies to develop more clinically applicable models for subclassifying patients according to genetic heterogeneity. Using simple immunohistochemistry techniques and tissue arrays, Hans and colleagues demonstrated that patients could be categorized into GCB and non-GCB subtypes based on the expression of six genes. In a separate study, Lossos and colleagues used polymerase chain reaction (PCR) technology to develop a prediction model based on the six genes with highest predictive capacity as identified in gene array studies. Efforts are currently under way to develop updated prognostic models that will combine both relevant clinical and molecular factors to further refine outcome prediction. This greater insight into the underlying biology of DLBCL may allow for the development of newer targeted therapeutic agents and tailored therapy options. However, it is not currently known how this information should be used to influence treatment decisions. Initial Treatment of Limited- Stage Disease Approximately 25% of patients with DLBCL present with limitedstage disease (stage I and non-bulky stage II). These patients have a variable outcome depending on the number of negative features present at diagnosis, with a 5-year overall survival ranging from 50% to 95%.[10,11] Using a stage-modified version of the IPI (including four factors: age > 60 years, elevated LDH, ECOG performance status ≥ 2, stage II disease), a very favorable subgroup can be identified (stage I with no risk factors) with a 5-year overall survival of greater than 90%, with remaining patients having a 5-year overall survival of approximately 70%. The presence of bulky stage II disease (≥ 10 cm) has been associated with a poorer prognosis; therefore, in North America these patients are treated similarly to those with advanced-stage lymphoma. Historically, patients with limitedstage disease treated with radiation therapy alone frequently relapsed at distant sites. Chemotherapy was introduced in an attempt to eradicate micrometastases and improve outcomes. The rationale for a combinedmodality approach using a brief course of chemotherapy followed by involved- field radiation therapy included maximizing local and systemic control and minimizing toxicity. With a median follow-up of 4.4 years, a large randomized trial performed by the Southwest Oncology Group (SWOG) compared combined-modality treatment-consisting of three cycles of CHOP (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], and prednisone) plus radiation therapy-with chemotherapy alone (eight cycles of CHOP). Investigators saw improved progressionfree survival, overall survival, and lesser toxicity with the combinedmodality approach. This trial was later updated with a median follow-up of 8.2 years. Kaplan-Meier estimates showed overlapping curves at 7 years for failurefree survival and at 9 years for overall survival, due to an increased numberof delayed relapses and deaths from lymphoma in the combined-modality group. Given its short duration, lower toxicity, and the early advantage seen in the first 7 to 9 years, combinedmodality therapy (brief chemotherapy and involved-field radiation) has remained the standard of care at many centers. Recently, Horning and colleagues updated results of a randomized trial comparing involved-field radiotherapy (30 Gy) vs no further treatment for limited-stage patients with aggressive diffuse lymphoma who achieved a complete remission (CR) following extended course chemotherapy (eight cycles of CHOP). Patients who achieved a partial remission (PR) were all treated with radiotherapy (40 Gy) in an attempt to induce a CR. Of note, this trial included patients with bulky stage II disease. Among 172 patients who achieved a CR following CHOP, the 6-year disease-free survival was improved in the radiotherapy group (73% vs 56%, P = .05), but no difference in overall survival was seen. For patients who achieved a PR and received radiotherapy, there seemed to be no advantage obtained from conversion to CR. In this trial, extending the therapy to eight cycles of CHOP and radiotherapy had no advantage over eight cycles of CHOP alone, and thus it may be inferred that eight cycles of CHOP and radiotherapy offers no advantage over three cycles of CHOP and radiotherapy. Several recent trials have reported results in favor of chemotherapy alone for patients with limited-stage aggressive lymphoma. The Groupe d'Etude des Lymphomes de l'Adulte (GELA) has reported results of a trial comparing the ACVBP regimen (an intensive schedule of doxorubicin [Adrimycin], cyclophosphamide, vindesine, bleomycin, and prednisone, followed by consolidation with methotrexate, ifosfamide, etoposide, and cytarabine) vs three cycles of CHOP and involved-field radiotherapy. This trial demonstrated a significant benefit for ACVBP in both 5-year event-free survival and overall survival. However, not only was ACVBP associated with significant toxicity, but this trial included patients with bulkystage II disease, a group that has been shown to do poorly with three cycles of CHOP and radiotherapy and should be treated the same as patients with advanced- stage lymphoma. A second trial reported by GELA compared four cycles of CHOP to four cycles of CHOP and involvedfield radiotherapy, for elderly patients (> 60 years) with limited-stage aggressive NHL and no adverse risk factors according to the age-adjusted IPI. In this trial, the addition of radiotherapy offered no advantage in terms of event-free or overall survival, and in the subgroup of patients who were older than 69 years, there was a survival advantage for chemotherapy alone. Although intriguing, this trial has only been presented in abstract form and further interpretation must await final publication. Initial Treatment of Advanced-Stage Disease Most patients with DLBCL present with advanced-stage disease at diagnosis. The CHOP chemotherapy regimen has been the mainstay of therapy since its development in the 1970s. Early attempts to improve outcomes through the creation of more intensive chemotherapy regimens by adding in non-cross-resistant drugs failed to show additional benefit. An American Intergroup trial randomized patients to one of three intensive chemotherapy regimens (MACOP-B, m- BACOD, ProMACE-CytaBOM)* or standard CHOP. This trial demonstrated that CHOP chemotherapy was as effective as the more intensive chemotherapy regimens, achieving a 3-year disease-free survival rate of 54%, with lesser toxicity. Thus, CHOP has remained the standard of care. Continued attempts to improve upon CHOP chemotherapy have focused on a variety of alternative chemotherapystrategies, including increased dose intensity (additional cytotoxic agents or higher doses) and increased dose density (interval reduction in drug delivery). The NHLB1 and NHL-B2 trials from Germany explored these strategies by randomizing patients to one of four different chemotherapy regimens: standard CHOP (CHOP-21), CHOP administered at 2-weekly intervals with granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) support (CHOP-14), or these same regimens with the addition of etoposide (CHOEP-14 or CHOEP-21).[21,22] The NHL-B1 trial included 710 young patients (ages 18-60 years) with good prognosis (normal LDH) aggressive NHL. The trial was analyzed according to the 2*2 factorial protocol design, comparing the two CHOP cohorts with the two CHOEP cohorts, and the two biweekly regimens with the two 3-week regimens independently. With a median observation time of 58 months, the addition of etoposide resulted in an improved 5-year event-free survival (69.2% vs 57.6%, P = .0004), but no difference in overall survival. The reduction to biweekly intervals did not significantly improve event-free survival in this young patient cohort, but did improve overall survival (P = .05). In NHL-B2, 689 elderly patients (ages 61-75 years) with newly diagnosed aggressive NHL were enrolled and eligible for evaluation. CHOP-14 resulted in a significant improvement in 5-year event-free survival (43.8% vs 32.5%) and 5-year overall survival (53.3% vs 40.6%) compared with standard CHOP-21. However, the addition of etoposide in this elderly subgroup caused a substantial increase in toxicity and offered no advantage in outcome. Examined together, these trials offer somewhat paradoxical results in these two different patient subgroups, making firm conclusions regarding the benefit of either approach difficult. The GELA compared the intensive conventional chemotherapy regimen ACVBP with standard CHOP in previously untreated patients with poor-risk aggressive NHL. A total of 635 elderly patients (ages 61-69 years) with at least one negative prognostic factor according to the ageadjusted IPI were eligible for evaluation. Both the 5-year event-free survival (39% vs 29%, P = .005) and the 5-year overall survival (46% vs 38%, P = .036) were significantly higher for patients treated with ACVBP. However, treatment-related deaths were higher in the ACVBP group (13% vs 7%, P = .014). In addition, an evaluation of patients treated on multiple trials of ACVBP demonstrated an increase in secondary myelodysplastic syndrome and acute leukemias, and an increase in lung cancer in men. Investigators at the National Cancer Institute in the United States have explored dose-adjusted EPOCH, an approach that combines infusional therapy with dose escalation to patient tolerance. This protocol involves the administration of etoposide, vincristine, and doxorubicin for 96 hours, with bolus doses of cyclophosphamide and prednisone. The doses of etoposide, doxorubicin, and cyclophosphamide were adjusted by 20% in each subsequent cycle to achieve a nadir neutrophil count of 0.5 * 109/L. Fifty previously untreated patients with large B-cell lymphomas were entered into a multi-institutional phase II trial. Median age was 48 (range: 20-88 years), and 44% had a high/intermediate- or high-risk IPI score. There was a high response rate (92% CR) and with a median follow-up time of 62 months, progression-free survival and overall survival were 70% and 73%, respectively. Investigators were able to escalate the doses in 58% of cycles. Initial use of high-dose therapy (HDT) and autologous stem cell transplantation has been investigated in aggressive NHL and remains controversial. Multiple studies have been reported, with conflicting results. While several studies have suggested a benefit for up-front autologous transplant for patients with poor-risk disease, others have been negative.[27,28] Recently, Milpied et al presented results of a randomized trial comparing HDT to standard CHOP in young patients (15-60 years) with untreated aggressive NHL with low-, low/intermediate-, or high/intermediate-riskdisease according to the age-adjusted IPI. A total of 197 patients were randomized; median follow-up was 4 years. The 5-year event-free survival was significantly improved in the HDT group (55% vs 37%, P = .037), but the 5-year overall survival did not meet statistical significance (71% vs 56%, P = .076). On subset analysis, only patients in the high-intermediate risk group seemed to benefit, with both an improvement in event-free and overall survival. This trial suggests some patients may benefit from HDT; however, many patients treated with HDT would likely have been cured with CHOP alone and were exposed to unnecessary toxicity. As HDT has been shown to cure a subset of patients with relapsed disease, it is likely that some patients may benefit from this treatment earlier in their course. The challenge remains trying to identify the appropriate subset that may benefit. An ongoing randomized trial being led by SWOG may further clarify the role of HDT in this setting. Thus far, none of these newer apapproaches have replaced CHOP as standard front-line therapy for aggressive NHL. Many trials have been performed in selected subgroups of patients, making generalizability difficult. In addition, the toxicity profiles have been substantially increased compared with CHOP. Most importantly, all of these trials have been performed prior to the availability of targeted therapy with monoclonal antibodies. Whether increasing dose intensity or dose density will offer an advantage when used in conjunction with a monoclonal antibody remains to be determined. Ongoing trials will help to answer these questions. Addition of Rituximab to Chemotherapy The era of monoclonal antibodies has transformed treatment practices for aggressive lymphoma and has led to a significant improvement in outcome. Rituximab (Rituxan), a chimeric anti-CD20 IgG1 monoclonal antibody, was approved by the USFood and Drug Administration (FDA) in 1997 for treatment of relapsed and refractory follicular lymphoma. Rituximab targets the CD20 cell surface protein present on mature B cells and most B-cell malignancies. Its effects are likely multifactorial and include complement-dependent cell lysis, cell-mediated cytotoxicity, and induction of apoptosis. Preclinical models suggested a synergistic effect when rituximab was combined with chemotherapy and early clinical trials demonstrated a minimal increase in toxicity. Early studies also indicated activity in DLBCL, with a single-agent response rate of 37%. The feasibility and safety of combining CHOP with rituximab was demonstrated in a phase II trial that reported a higher than expected CR rate of 61%. The GELA Trial The GELA performed the first randomized, controlled trial demonstrating the benefit of adding rituximab tochemotherapy for the treatment of DLBCL. This trial compared eight cycles of CHOP chemotherapy to eight cycles of rituximab and CHOP (R-CHOP) in elderly patients (age ≥ 60 years) with newly diagnosed advanced stage DLBCL. Rituximab was administered at 375 mg/m2 on day 1 with each cycle of CHOP. A total of 399 patients were included in this trial: 197 in the CHOP arm and 202 in the R-CHOP arm. Patients in the R-CHOP arm had a higher response rate (CR/unconfirmed CR rate 75% vs 63%, P = .005) and a lower rate of progression on treatment (9% vs 22%), resulting in both a significantly improved event-free and overall survival. These results have been recently updated with a median follow-up time of 5 years. The benefit seen with the addition of rituximab has been maintained over time, indicating an improvement in the cure rate for this patient population (5-year event-free survival 47% vs 29%, P = .00002; 5-year overall survival 58% vs 45%, P = .0073) (Figure 1). The addition of rituximab did not result in any increase in clinically relevant toxicity. Subgroup analyses of the GELA trial have demonstrated several interesting observations. Patients were stratified according to age-adjusted IPI, and both the low- and high-risk patients were shown to benefit from the addition of rituximab. However, patients in the low risk group seemed to experience the greatest degree of benefit. Outcome was also analyzed according to the level of bcl-2 protein expression. The impact of the addition of rituximab to CHOP was largely seen in patients who overexpressed bcl-2, suggesting that rituximab could overcome the chemotherapy resistance seen in this patient subset. The US Intergroup Trial Preliminary results of a US Intergroup trial also examining the use of rituximab and CHOP in elderly patients (age ≥ 60 years) with newly diagnosed advanced-stage DLBCL were presented at the American Society of Hematology (ASH) annual meeting in 2003, and updated atASH 2004. This study had a double randomization design and compared induction therapy with CHOP vs R-CHOP followed by maintenance rituximab vs observation for responding patients. Rituximab maintenance was administered as four infusions every 6 months for 2 years. This study differed from the GELA trial in that rituximab was administered on a different schedule (two doses prior to starting CHOP, then with every other cycle of CHOP); patients received six to eight cycles of CHOP according to the response observed after four cycles; and half of responding patients received maintenance therapy with rituximab. A total of 546 patients were evaluable for induction and 352 for maintenance. Overall response rates were not different for R-CHOP (79%) vs CHOP induction (76%) (P = .92). With a median follow-up time of 3.5 years, time to treatment failure favored R-CHOP induction (53% vs 46% at 3 years, P = .04), but no survival advantage was seen. Regarding maintenance, patients receiving rituximab had a significantly prolonged time to treatment failure (P = .009), but no difference in overall survival. The time to treatment failure was prolonged with maintenance rituximab after CHOP (P = .0004) but not after R-CHOP (P = .81), demonstrating that there was no apparent benefit for maintenance rituximab if patients had received R-CHOP induction. However, this also confirmed that the use of maintenance rituximab confounded the induction analysis. In an attempt to eliminate the interaction between induction and maintenance, the authors performed two secondary analyses. A weighted analysis (excluding patients who received maintenance rituximab) demonstrated that the addition of rituximab to CHOP induction resulted in both a significantly improved time to treatment failure (52% vs 39% at 3 years, P = .003) and overall survival (67% vs 58% at 3 years, P = .05), confirming results of the GELA trial. A fourarm analysis of responding patients entering the second randomization demonstrated that time to treatment failure was significantly better in patientswho had received rituximab at any time during their course of therapy, and suggested that the addition of rituximab to CHOP had an additive, rather than synergistic, effect. The British Columbia Population Analysis Based on initial encouraging results of the GELA trial, on March 1, 2001, the British Columbia Cancer Agency implemented a new provincial policy recommending the use of R-CHOP for all newly diagnosed patients with advanced stage DLBCL, regardless of age. A population-based retrospective analysis was performed, comparing outcomes in patients treated with a CHOP-like regimen with curative intent over an 18-month period prior to the introduction of rituximab (pre-rituximab) and the 18 months following (post-rituximab) the policy change. A total of 294 patients were identified (142 pre-rituximab, 152 post-rituximab) using three independent data sources: the British Columbia Provincial Cancer Registry, British Columbia Cancer Pharmacy records, and the Lymphoma Clinical Database. Clinical characteristics were similar in both groups. The median age was 63 years (range: 19-86 years) with no differences in distribution of IPI scores. Patients received rituximab with each cycle of CHOP at the standard dose of 375 mg/m2. Although the policy implementation date was March 1, 2001, 9% of the pre-rituximab patients received rituximab with chemotherapy and 15% of the post-rituximab patients did not receive rituximab. Results were analyzed based on the intended policy implementation date. Median follow-up was 34 months for the pre-rituximab patients and 17 months for post-rituximab patients. At 2 years, both the progression-free survival (71% vs 52%, P = .0009) and overall survival (77% vs 53%, P = .0001) were significantly improved in the post-rituximab group (Figure 2). An improvement in overall survival was seen in both younger (age < 60 years) and older (age ≥ 60 years) patients (Figure 3). In a multivariate analysis controlling for age, B symptoms, and IPI score, the era of treatment remained a strong, independent predictor of outcome for both progression- free and overall survival. This study confirmed results of the GELA and Intergroup trials and demonstrated the profound impact of theaddition of rituximab to CHOP when administered to an unselected population of patients with DLBCL in routine clinical practice. This study was also the first to report a benefit of combined chemotherapy and rituximab for younger patients with DLBCL. The MInT Trial The MabThera International Trial (MInT) evaluating CHOP-like chemotherapy with or without the addition of rituximab in young patients (age ≤ 60 years) with a favorable prog-nostic profile (IPI score 0 or 1) has recently been reported. The first complete analysis of 823 evaluable patients was presented at ASH 2004. As in the GELA trial, the addition of rituximab resulted in a higher response rate and a lower rate of progression. With a median follow-up of 22 months, both 2-year time to treatment failure (76% vs 60%, P < .00001) and 2-year overall survival (94% vs 87%, P < .001) were significantly improved in patients who received rituximab. The combined weight of these three randomized studies, together with the British Columbia population analysis, confirms the substantial benefit of combination therapy and has established CHOP and rituximab as the new standard of care for all patients with advanced-stage DLBCL. While the above studies primarily targeted patients with advanced-stage disease, Miller and colleagues have recently reported results on 62 evaluable patients with limited-stage DLBCL treated with four cycles of rituximab added to the standard three cycles of CHOP and radiation therapy.[ 42] With a median follow-up of 2.4 years, progression-free and overall survival measured at 2 years were 94% and 95%, respectively. Outcomes were compared to a historical group of patients (n = 68), with similar characteristics treated in a prior SWOG study of three cycles of CHOP and radiation therapy. The 2-year progression- free survival seemed more favorable in patients who received rituximab (94% vs 85%), suggesting a benefit of rituximab in patients with limited-stage disease. Secondary Therapy The PARMA trial established HDT and stem cell transplantation as the treatment of choice for aggressive lymphoma patients (< 60 years) with chemosensitive disease in first relapse.[ 43] This trial compared a standard salvage chemotherapy regimen, DHAP (dexamethasone, cisplatin, cytarabine),with HDT and demonstrated a survival advantage in favor of HDT (53% vs 32% at 5 years, P = .038). A variety of such secondary or salvage chemotherapy regimens have been used prior to transplantation or for patients who are transplant ineligible. No comparative trials of salvage regimens have been performed and therefore no consensus exists regarding the optimal regimen. Recent studies incorporating rituximab with a variety of standard salvage regimens have demonstrated high response rates. Kewalramani and colleagues compared patients treated with R-ICE (rituximab with ifosfamide, carboplatin [Paraplatin], etoposide) (n = 36) to a historical group of similar patients treated with ICE alone (n = 147) prior to HDT. Patients in the R-ICE cohort had higher response rates (CR rate 53% vs 27%, P = .01), a trend toward improved progression-free survival (54% vs 45%, P = .25), but no difference in overall survival. None of the patients in this study had received rituximab with first-line treatment. Therefore, the value of rituximab with salvage therapy in patients who have failed a combination of chemotherapy and rituximab up front remains unknown. Rituximab has been used prior to HDT and stem cell transplantation (as an in vivo purging agent), as well as after HDT to eradicate minimal residual disease. A recent phase II study investigating the use of post-transplantation rituximab in aggressive NHL yielded encouraging results (2-year event-free survival 83%; 2-year overall survival 88%). Ongoing randomized trials will help to clarify choice of salvage chemotherapy and the role of rituximab in conjunction with HDT for relapsed patients. PET Scanning The utility of 18FDG-positron emission tomography (PET) scanning in the assessment of aggressive NHL has been well demonstrated. PET scanning is a functional imaging technique that allows the differentiation of benign from malignant tissue based on glucose uptake. It has been shown to be a more sensitive and specific radiologicmodality than CT scanning. However, there are no data demonstrating that an improved outcome results from the routine use of PET scanning for staging of aggressive NHL. PET scans performed following completion of treatment for NHL have been shown to be highly predictive of outcome. Spaepen and colleagues evaluated the utility of post-treatment PET scans in 93 patients with NHL. All 26 patients with a positive PET scan following therapy went on to relapse, whereas only 11 of 67 patients (16%) with a negative PET scan relapsed. There was a highly significant association between PET scan results post-treatment and progression- free survival (P < .00001). Early restaging PET scanning performed after one to four cycles of therapy has also been shown to be highly predictive of outcome.[49,50] In a prospective trial, 70 patients with aggressive NHL underwent PET scanning after three/four cycles of doxorubicin-based chemotherapy. None of the 33 patients with a positive midtreatment PET scan achieved a durable CR, whereas 31 out of 37 (84%) patients with a negative midtreatment PET scan remain in remission. In multivariate analysis, PET scanning at midtreatment was a stronger prognostic factor for progressionfree survival (P < .0000001) and overall survival (p < .000009) than the IPI. These results demonstrate that PET scanning is a powerful tool for assessing response to therapy in aggressive lymphoma, and will become increasingly used to guide treatment planning. Newer Therapies While the addition of rituximab has been a major advance in the management of aggressive NHL, newer therapies are needed and many are under active investigation. Newer monoclonal antibodies are being evaluated. Alemtuzumab (Campath), an anti- CD52 humanized monoclonal antibody routinely used in chronic lymphocytic leukemia, has shown limited utility in aggressive lymphomas, with the exception of peripheral T-cell lymphoma. Fully human-ized anti-CD20 monoclonal antibodies targeting a different epitope on the CD20 molecule than rituximab have shown initial promise in early phase trials for lymphoma. Epratuzumab, an anti-CD22 humanized monoclonal antibody, has been primarily evaluated in indolent lymphoma. A recent dose-finding study performed in aggressive NHL demonstrated some clinical utility with an objective response rate of 10% to 15%. Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is undergoing evaluation in early-phase trials in conjunction with R-CHOP for DLBCL. Two radiolabeled anti-CD20 monoclonal antibodies (tositumomab and ibritumomab tiuxetan) have been approved for the treatment of relapsed follicular and transformed lymphoma.[ 55,56] These agents are under active investigation as part of conditioning therapy for autologous transplantation and following R-CHOP chemotherapy for aggressive lymphoma. Numerous chemotherapeutic agents and targeted molecules are being actively investigated. Bcl-2 antisense has shown evidence of activity in NHL, and trials are under way in combination with R-CHOP for newly diagnosed aggressive lymphoma. Bortezomib (Velcade) has shown promise in mantle cell lymphoma, but only limited data are available regarding its utility in other aggressive lymphomas. In a recent study, only one partial response was observed in 12 patients treated with bortezomib for relapsed or refractory DLBCL. Gene array studies have identified overexpression of PKC-b to be associated with a poorer prognosis in DLBCL. Trials investigating agents that target this enzymatic pathway have recently been initiated. Conclusions Advances in molecular biology have allowed an increased understanding of the heterogeneity of NHL, including aggressive histologies such as DLBCL. The addition of rituximab has been the first major improvement in therapy in 2 decades for patientswith this aggressive lymphoma. However, the pace of further improvement is likely to be much more rapid. The insights from powerful new molecular techniques such as gene expression profiling should permit identification of additional lymphoma specific therapeutic targets. Newer chemoimmunotherapeutic agents, such as proteosome inhibitors, histone deacetylase inhibitors, and novel monoclonal antibodies, are already being tested in phase II clinical trials. The potential of radioimmunoconjugates has yet to be fully realized. Integration of functional imaging techniques such as PET scanning into therapeutic decision-making has major potential to alter current treatment algorithms. Further advances identifying newer targeted agents that take into account underlying biology and allow for greater tailoring of therapy will almost certainly result from these novel approaches. The key to rapid translation of these new techniques into routine patient management will remain the proper design and conduct of innovative clinical trials-rials that will continue to deserve the wide support of North American oncologists.
Dr. Sehn and Dr. Connors have received research sponsorship from and acted as consultants to Hoffman La Roche (Roche Canada).
1.fe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001.
2. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993.
3. Gascoyne RD: Emerging prognostic factors in diffuse large B cell lymphoma. Curr Opin Oncol 16:436-441, 2004.
4. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.
5. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002.
6. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002.
7. Monti S, Savage KJ, Kutok JL, et al: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including onecharacterized by host inflammatory response. Blood 105:1851-1861, 2005.
8. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004.
9. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-Bcell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004.
10. Shenkier TN, Voss N, Fairey R, et al: Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20:197-204, 2002.
11. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339:21-26, 1998.
12. Miller TP, LeBlanc M, Spier C, et al: CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non- Hodgkin’s lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 98:724a-725a, 2001.
13. Fisher RI, DeVita VT, Jr., Johnson BL, et al: Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 63:177- 182, 1977.
14. Chen MG, Prosnitz LR, Gonzalez-Serva A, et al: Results of radiotherapy in control of stage I and II non-Hodgkin’s lymphoma. Cancer 43:1245-1254, 1979.
15. Connors JM, Klimo P, Fairey RN, et al: Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 107:25- 30, 1987.
16. Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in limited- stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032-3038, 2004.
17. Reyes F, Lepage E, Munck JN, et al: Superiority of chemotherapy alone with the ACVBP regimen over treatment with three cycles of CHOP plus radiotherapy in low risk localized aggressive lymphoma: The LNH93- 1 GELA Study. Blood 100:93a, 2002.
18. Fillet G, Bonnet C, Mounier N, et al: Radiotherapy is unnecessary in elderly patients with localized aggressive non-Hodgkin’s lymphoma: Results of the GELA LNH 93-4 study. Blood 100:92a, 2002.
19. McKelvey EM, Gottlieb JA, Wilson HE, et al: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976.
20. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002-1006, 1993.
21. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004.
22. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004.
23. Tilly H, Lepage E, Coiffier B, et al: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289, 2003.
24. Andre M, Mounier N, Leleu X, et al: Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood 103:1222-1228, 2004.
25. Wilson WH, Grossbard ML, Pittaluga S, et al: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 99:2685-2693, 2002.
26. Shipp MA, Abeloff MD, Antman KH, et al: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non- Hodgkin’s Lymphomas: Report of the jury. J Clin Oncol 17:423-429, 1999.
27. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87-2 protocol—A Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 18:3025-3030, 2000.
28. Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997.
29. Milpied N, Deconinck E, Gaillard F, et al: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287- 1295, 2004.
30. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
31. Anderson DR, Grillo-Lopez A, Varns C, et al: Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non- Hodgkin’s B-cell lymphoma. Biochem Soc Trans 25:705-708, 1997.
32. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997.
33. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927-1932, 1998.
34. Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 19:389-397, 2001.
35. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002.
36. Coiffier B, Feugier P, Sebban C, et al: Long term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell lymphoma. Blood 104:388a, 2004.
37. Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279- 4284, 2003.
38. Habermann TM, Weller EA, Morrison VA, et al: Phase III trial of Rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL) (abstract). Blood 102:6, 2003.
39.Habermann T, Weller E, Morrison VA, et al: Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update. Blood 104:40a, 2004.
40. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOPRituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC) (abstract). Blood 102:29, 2003.
41. Pfreundschuh M, Trumper L, Gill D, et al: First analysis of the completed Mabthera International (MInT) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOPlike regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Blood 104:48a, 2004.
42. Miller TP, Unger JM, Spier C, et al: Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood 104:48a, 2004.
43. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin’s lymphoma. N Engl J Med 333:1540- 1545, 1995.
44. Coiffier B: Effective immunochemotherapy for aggressive non-Hodgkin’s lymphoma. Semin Oncol 31:7-11, 2004.
45. Kewalramani T, Zelenetz AD, Nimer SD, et al: Rituximab and ICE (RICE) as secondline therapy prior to autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103:3684-3688, 2004.
46. Horwitz SM, Negrin RS, Blume KG, et al: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777-783, 2004.
47.Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non- Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999.
48. Spaepen K, Stroobants S, Dupont P, et al: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419, 2001.
49. Spaepen K, Stroobants S, Dupont P, et al: Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non- Hodgkin’s lymphoma. Ann Oncol 13:1356- 1363, 2002.
50. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43:1018-1027, 2002.
51. Enblad G, Hagberg H, Erlanson M, et al: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral Tcell lymphomas. Blood 103:2920-2924, 2004.
52. Hagenbeek A, Plesner T, Waleswski J, et al: HuMax-CD20 fully human monoclonal antibody in follicular lymphoma. First human exposure: Early results of an ongoing phase I/II trial. Blood 104:393a, 2004.
53. Leonard JP, Coleman M, Ketas JC, et al: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: Phase I/II clinical trial results. Clin Cancer Res 10:5327-5334, 2004.
54. Ganjoo KN, Gordon L, Robertson MJ, et al: Rituximab, bevacizumab (Avastin) and CHOP (RA-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL). Blood 104:389a, 2004.
55. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 19:3918-3928, 2001.
56. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmuno-therapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453-2463, 2002.
57. Chanan-Khan A, Czuczman MS: Bcl-2 antisense therapy in B-cell malignant proliferative disorders. Curr Treat Options Oncol 5:261-267, 2004.
58. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non- Hodgkin’s lymphoma. J Clin Oncol 23:667- 675, 2005.